Company Overview and News

 
NZ shares inch higher as investors eye upcoming AGMs

11h nzherald.co.nz
New Zealand shares edged higher as investors wait for the upcoming round of annual meetings for a clearer steer on company outlooks.
CEN AIR FCREY NZTCF ACKDF ANZFY AUKNY AIZ COENF SKT SYKWF CEN SKKTY AIA FBU SPKKY NZTCY SPK FRCEF COENY AIA FBU ANZLY OHE ANZFF MEZ

 
Shares rise as Tourism Holdings upgraded

2018-09-20 nzherald.co.nz
New Zealand shares edged higher as Tourism Holdings snapped a seven-day slide on a broker upgrade. Spark New Zealand was among several companies shedding rights to dividends.
CEN BGR FBU AIR FCREY SPKKY NZTCY SPK NZTCF FRCEF ANZFY COENY AIZ COENF GNE FBU THL ANZLY CEN ANZFF GNE MEZ GEL

 
NZ shares shrug off Synlait slump, join global rally

2018-09-19 nzherald.co.nz
New Zealand shares rose as investors shrugged off a slightly gloomier outlook for Synlait Milk and joined a global rally as the latest bout in the US-China trade war wasn't as harsh as feared.
KTHDY WBC SPKKY NZTCY SPK NZTCF WEBNF WBK KMD WBC PPSHY THL MS KMD SML

1
Vodafone NZ float on the cards for 2019 - FT report

2018-09-17 nzherald.co.nz
Vodafone Group's incoming chief executive Nick Read says a float of the New Zealand unit is on the cards next year.
SKT SYKWF VOD VOD VODPF NZTCY SPKKY SKKTY SPK NZTCF

 
NZ shares gain, led by Pushpay

2018-09-14 nzherald.co.nz
New Zealand shares joined the global rally in equity markets as the prospect of improving trade relations between the US and China lifted investor confidence. Pushpay Holdings led the market higher after getting a broker upgrade.
AIA FBU AIR FCREY SPKKY NZTCY SPK NZTCF ACKDF FRCEF ANZFY AUKNY AIZ FTRRF AIA PPSHY FBU THL ANZLY ANZFF

 
Trade Me leads NZ shares gain

2018-09-13 nzherald.co.nz
New Zealand shares rose, joining a regional rally on optimism over US-China trade relations. Fonterra Cooperative Group's first annual loss dominated local headlines.
CEN AIR FCREY NZTCF ACKDF ANZFY AUKNY AIZ KMD COENF GNE CEN KMD GEL SML KTHDY AIA FBU SPKKY NZTCY SPK FRCEF COENY AIA FBU ANZLY ANZFF GNE MEZ

 
NZ shares fall as investors cash in August gains; Tourism Holdings, A2 drop

2018-09-07 nzherald.co.nz
New Zealand shares fell for a third session, taking their weekly decline to 2.3 per cent, as investors cashed in some of August's gains in what was a strong month for the local market. Tourism Holdings and a2 Milk Co declined.
WYN AIR FCREY NZTCF RYM ACKDF ANZFY AUKNY AIZ KMD SKT SYKWF SKKTY KMD SML KTHDY AIA FBU RHCGF SPKKY NZTCY SPK FRCEF AIA FBU THL ANZLY RYHTY OHE ANZFF MEZ

 
NZ shares gain, led by Sky TV

2018-09-04 nzherald.co.nz
New Zealand shares rose as investors weigh up the prospect of a potential rate cut, spurring demand for stocks with high dividends, in a world economy that remains relatively robust. Sky Network Television, Spark New Zealand and Chorus gained.
KTHDY CEN PGC SPKKY NZTCY SPK NZTCF COENY KMD COENF SKT SYKWF CEN SKKTY KMD

 
Vodafone profit slumps $7.7M as margins tighten

2018-09-03 nzherald.co.nz
Vodafone New Zealand reported a 16 per cent slide in annual profit as the country's biggest mobile carrier's margins were squeezed by more expensive handsets and content costs, and a bigger wage bill.
NZTCY SPKKY SPK NZTCF

 
Spark New Zealand Limited ADR (SPKKY) Q4 2018 Results - Earnings Call Transcript

2018-08-24 seekingalpha
Spark New Zealand Limited ADR (OTCPK:SPKKY) Q4 2018 Results Earnings Conference Call August 21, 2018 6:00 PM ET
WHOSY SPKKY NZTCY SPK NZTCF WHGPF WHS

 
NZ shares drop as Air NZ, Ebos fall

2018-08-23 nzherald.co.nz
New Zealand shares dropped as investors picked a weaker outlook for Air New Zealand and Ebos. Fisher & Paykel Healthcare Corp and Auckland International Airport gained on expectations for continuing strong earnings growth.
TME AIA TRMEF WBC AIR SPKKY NZTCY SPK NZTCF WEBNF WBK ACKDF ANZFY AUKNY AIZ AIA WBC PPSHY ANZLY TME ANZFF TDMEY

 
Spark New Zealand Limited ADR 2018 Q4 - Results - Earnings Call Slides

2018-08-22 seekingalpha
The following slide deck was published by Spark New Zealand Limited ADR in conjunction with their 2018 Q4 earnings call.
SPKKY NZTCF

 
NZ shares hit record, led by Pushpay

2018-08-22 nzherald.co.nz
New Zealand shares hit another record amidst a slew of earnings, with Trade Me Group and A2 Milk Co gaining on their annual accounts while Fletcher Building dropped.
TME TRMEF FBU WBC FCREY SPKKY NZTCY SPK NZTCF WEBNF WBK FRCEF WBC PPSHY FBU TME TDMEY MEZ

 
Spark vs Vodafone: who's winning the mobile war

2018-08-21 nzherald.co.nz
Vodafone is winning the telecommunications rat race when it comes to the rate of signing on more mobile customers.
NZTCY SPKKY SPK NZTCF

 
Spark profit falls on restructuring costs

2018-08-21 nzherald.co.nz
Spark New Zealand posted a 7.9 per cent decline in annual profit as the country's biggest telecommunications company booked restructuring costs as it chases the mantle of being the lowest cost operator.
NZTCY SPKKY SPK NZTCF

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 688143007